NSD1 inactivating mutations have been reported to occur at a frequency of 10–13% and correlate with a better prognosis for HNSCC patients [9, 12, 13], especially among patients with HPV-negative laryngeal tumors [9], in the analysis of a cohort of patients in which treatment with chemoradiation was common. Here, NSD1 is linked to head and neck squamous cell carcinoma.